Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GRAILGRAL +0.03%11 3-Year EPS without NRI Growth Rate is 23.70% as of Jun. 2026. GuruFocus rates GRAL with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 161 Medical Diagnostics & Research companies, GRAIL ranks better than 63.35% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 23.70% per year.
During the past 5 years, the average EPS without NRI Growth Rate was -11.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 7 years, the highest 3-Year average EPS without NRI Growth Rate of GRAIL was 23.70% per year. The lowest was -40.70% per year. And the median was -40.30% per year.
GRAIL (NAS:GRAL) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
GRAIL 3-Year EPS without NRI Growth Rate Related Terms
GRAL vs VCYT, ADPT, BLLN: 3-Year EPS without NRI Growth Rate Comparison
For the Diagnostics & Research subindustry, GRAIL's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GRAIL 3-Year EPS without NRI Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, GRAIL's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where GRAIL's 3-Year EPS without NRI Growth Rate falls into.
GRAIL 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 23.70% mean?
GRAIL (GRAL) has a 3-Year EPS without NRI Growth Rate of 23.70% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for GRAIL and its competitors. According to the industry distribution chart, GRAIL ranks #59 out of 161 companies in the Medical Diagnostics & Research industry, placing it in the top 36.6%.
Is GRAIL's 3-Year EPS without NRI Growth Rate too high?
GRAIL's current 3-Year EPS without NRI Growth Rate is 23.70%. The Medical Diagnostics & Research industry median 3-Year EPS without NRI Growth Rate is 10.70. GRAIL's value of 23.70% is 121.5% above this industry median. Based on the distribution chart, GRAIL ranks #59 out of 161 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, GRAIL has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does GRAIL's 3-Year EPS without NRI Growth Rate compare to VCYT and ADPT?
According to the Medical Diagnostics & Research industry distribution chart, GRAIL ranks #59 out of 161 companies for 3-Year EPS without NRI Growth Rate. This puts GRAIL in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 10.70. GRAIL's value of 23.70% is 121.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EPS without NRI Growth Rate among Medical Diagnostics & Research companies is 10.70, based on 161 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GRAIL's current 3-Year EPS without NRI Growth Rate of 23.70% is 121.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for GRAIL and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EPS without NRI Growth Rate is 10.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GRAIL's current 3-Year EPS without NRI Growth Rate is 23.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GRAIL stock overvalued right now?
GRAIL (GRAL) has a current 3-Year EPS without NRI Growth Rate of 23.70%. The current 3-Year EPS without NRI Growth Rate is 23.70% and 121.5% above the Medical Diagnostics & Research industry median of 10.70. GRAIL's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For GRAIL (GRAL), the current 3-Year EPS without NRI Growth Rate is 23.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
11GF Score
Get the complete analysis for GRAL
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRAL has been successfully added to your 
